317-622-8970 Back to results

Catalyst Pharmaceuticals

Commercial services · Coral Gables, Florida

Industrial & mechanicalCommercial services
Coral Gables, Florida, United States181 employees$411.3M revenue
Visit Website

Find prospects like Catalyst Pharmaceuticals

Get a list of similar companies, matched by industry, size and location, ready for outreach.

Free sample of 25 companies by email within one business day. No spam: we only use your email for this request.

Products & Services

Industrial & mechanicalCommercial servicesOffice serviceneurologyneuromuscularpharmaceuticalsrare disease

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc (Catalyst) develops innovative therapies for the treatment of orphan neuromuscular and neurological diseases and disorders. The company’s products under development include Firdapse (amifampridine phosphate), CPP-115 and CPP-109. Firdapse (amifampridine phosphate), chemically known as 3,4- diaminopyridine or 3, 4-DAP, is a voltage-gated potassium channel blocker. It is indicated for Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse (amifampridine phosphate) completed Phase II trial for CMS and Phase III trial for LEMS. It is also being assessed as a treatment for refractory types of MuSK-antibody positive myasthenia gravis (MG) or other similar and rare neuromuscular diseases. The company has in-licensed North American rights to Firdapse (amifampridine phosphate) from BioMarin Pharmaceutical Inc. The US Food and Drug Administration (FDA) granted Breakthrough therapy designation for Firdapse for LEMS and Orphan drug designation for amifampridine phosphate for the treatment of LEMS, CMS and MG. CPP-115 is a second generation GABA aminotransferase inhibitor, and a potent form of vigabatrin. It inhibits GABA-aminotransferase (GABA-AT) to enhance the endogenous GABA levels in the brain and balance its inhibitory effects. CPP-115 is under development for the treatment of infantile spasms, complex partial seizures and Tourette’s disorder (TD). It is under Phase II trial for TD and completed Phase I trial in infantile spasms. Catalyst was granted orphan medicinal product designation by the European Union for CPP-115 for the treatment of West Syndrome (infantile spasms). CPP-109 (vigabatrin) is the first generation GABA-aminotransferase (GABA-AT) inhibitor. It is the generic version of Sabril (vigabatrin), marketed by Lundbeck Inc. in the US for the treatment of infantile spasms and complex partial seizures. CPP-109 is indicated as an add-on treatment for TD. The company develops product candidates through contracts with drug manufacturers and other vendors, including clinical research organizations. Catalyst has licensing agreement with New York University (NYU) and the Feinstein Institute for Medical Research, under which it acquired the worldwide rights to commercialize GABA aminotransferase inhibitors; and licensing agreement with BioMarin for Firdapse, under which it acquired the North American rights. The company focuses on research and development (R&D) to develop CPP-109, CPP-115 and Firdapse. In FY2016, the company spent US$11.3 million on its R&D activities.

Its primary NAICS classification is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)). Catalyst Pharmaceuticals is one of 2,003,955 Industrial & mechanical companies listed in Florida.

Business Contact Information

Phone
(305) 420-3200
Fax
(305) 529-0933
Address
355 Alhambra Cir, Coral Gables, Florida, 33134, United States

Industry & Classification

Industry
Industrial & mechanical
Sector
Commercial services
Segment
Office service
IndustryIndustrial & mechanicalCommercial servicesOffice service

NAICS Codes

  • 54Professional, Scientific, and Technical Services
  • 541Professional, Scientific, and Technical Services
  • 5417Scientific Research and Development Services
  • 54171Research and Development in the Physical, Engineering, and Life Sciences
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 32
  • 325Chemical Manufacturing
  • 3254Pharmaceutical and Medicine Manufacturing
  • 32541Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
  • 5413Architectural, Engineering, and Related Services
  • 54138Testing Laboratories and Services
  • 541380Testing Laboratories and Services

SIC Codes

  • 87Engineering, Accounting, Research, Management, And Related Services
  • 873Research, Development, And Testing Services
  • 8731
  • 8734Testing Laboratories
  • 28Chemicals And Allied Products
  • 283Drugs
  • 2834Pharmaceutical Preparation Mfg.

Company Details

Employees
181
Annual Revenue
$411.3M

Catalyst Pharmaceuticals: frequently asked questions

What does Catalyst Pharmaceuticals do?

Catalyst Pharmaceuticals Inc (Catalyst) develops innovative therapies for the treatment of orphan neuromuscular and neurological diseases and disorders. The company’s products under development include Firdapse (amifampridine phosphate), CPP-115 and CPP-109.

Where is Catalyst Pharmaceuticals located?

Catalyst Pharmaceuticals is located at 355 Alhambra Cir, Coral Gables, Florida, 33134, United States.

How many employees does Catalyst Pharmaceuticals have?

Catalyst Pharmaceuticals has about 181 employees.

What is Catalyst Pharmaceuticals's annual revenue?

Catalyst Pharmaceuticals's annual revenue is estimated at $411.3M.

What industry is Catalyst Pharmaceuticals in?

Catalyst Pharmaceuticals is in the Industrial & mechanical / Commercial services industry, and its primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

How can I contact Catalyst Pharmaceuticals?

Its website is www.catalystpharma.com and its phone number is (305) 420-3200.

What companies are similar to Catalyst Pharmaceuticals?

Other large industrial & mechanical companies in Florida include Deloitte, PwC, State of Florida and Florida Department of Education.

Largest industrial & mechanical companies in Florida

Largest companies in Florida

Largest industrial & mechanical companies

Manufacturing sales in Florida, 2026

In Florida, Factur's 2026 study counted 54 manufacturing quotes worth $10.7M and 9 purchase orders over 12 months: 17% of quotes became orders, against 21% nationally. See the Florida data.

Own this business?

Keep your profile accurate — or ask us to take it down. We acknowledge requests within 7 days and resolve them within 30 days.

Prefer email? privacy@facturmfg.com

Add this badge to your website — show visitors you're listed on Factur Data.